Sign In
Buy QTRX
$3.49
+0.100 (+2.95%)
At Close: Jun 22, 2026
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Tuesday, 16'th Jun 2026
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery
Quanterix Corporation (QTRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
12:22am, Wednesday, 10'th Jun 2026
Quanterix Corporation (QTRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Quanterix Announces Appointment of Jason Faessler as Chief Financial Officer
08:03am, Tuesday, 09'th Jun 2026
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the ap
Quanterix Appoints Industry Veteran Geoff Albrecht as Senior Vice President and General Manager of Diagnostics
09:00am, Thursday, 04'th Jun 2026
Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced
Quanterix Appoints Industry Veteran Geoff Albrecht as Senior Vice President and General Manager of Diagnostics
08:02am, Thursday, 04'th Jun 2026
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the ap
Quanterix To Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
08:01am, Wednesday, 03'rd Jun 2026
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that s
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Tuesday, 26'th May 2026
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery
Quanterix Announces Planned Transition of Chief Financial Officer
04:01pm, Tuesday, 12'th May 2026
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that V
Quanterix Corporation (QTRX) Q1 2026 Earnings Call Transcript
07:21pm, Wednesday, 06'th May 2026
Quanterix Corporation (QTRX) Q1 2026 Earnings Call Transcript
Quanterix Corporation (QTRX) Reports Q1 Loss, Lags Revenue Estimates
06:25pm, Wednesday, 06'th May 2026
Quanterix Corporation (QTRX) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.53 per share a year ago.
Quanterix Releases Financial Results for the First Quarter of 2026
04:01pm, Wednesday, 06'th May 2026
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced financ
Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows
08:00am, Wednesday, 06'th May 2026
BILLERICA, Mass.--(BUSINESS WIRE)--Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), today announced a collaboration with Tempus AI Inc. (NASDAQ: TEM), a technology company leading
Quanterix To Report First Quarter 2026 Financial Results on May 6, 2026
08:33am, Friday, 24'th Apr 2026
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that i
AidaBREAST™ Multi-Omic Assay Demonstrates Spatial Proteomics for Clinical Oncology
08:33am, Friday, 17'th Apr 2026
LAGUNA HILLS, Calif. & BILLERICA, Mass.--(BUSINESS WIRE)--PreludeDx® and Quanterix Corporation (Nasdaq: QTRX) today highlighted that AidaBREAST™, the first multi-omic assay to predict both locoregi
Quanterix Debuts Content Innovation Engine at AACR 2026
08:33am, Wednesday, 15'th Apr 2026
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX) today announced plans to debut its Content Innovation Engine at the American Association for Cancer Research (AACR) Annual Meeti
